Non Animal Testing, Alternative Test Methods, In Vitro Toxicology, IIVS | Respiratory Toxicology
242
archive,tag,tag-respiratory-toxicology,tag-242,ajax_fade,page_not_loaded,,qode_grid_1300,footer_responsive_adv,hide_top_bar_on_mobile_header,qode-content-sidebar-responsive,qode-child-theme-ver-,qode-theme-ver-17.2,qode-theme-bridge,disabled_footer_bottom,qode_header_in_grid,wpb-js-composer js-comp-ver-5.6,vc_responsive

Respiratory Toxicology Tag

Post-doctoral Scientist (Respiratory Toxicology Program)

May 6, 2019
We are seeking a full time Post-doctoral Scientist (who may serve in a Study Director role, as applicable) to assist in the Respiratory Toxicology Program in our Gaithersburg office. Experience/education in in vitro and/or ex vivo toxicology is required, with experience in respiratory sensitization, or immunological processes germane to the science, necessary. A background and/or familiarity with long term pulmonary disease processes (e.g. chronic inflammation, fibrosis, COPD) is highly desired. This is an exciting opportunity to join and grow with our...

Register For ICCVAM’s Free Webinar on In Vitro Inhalation Toxicity Testing

January 10, 2019
NICEATM will organize a free webinar on behalf of ICCVAM on January 22, 2019 between 1:00-2:30 p.m. Eastern Time.  Registration will be required. Topics will include an overview of ongoing collaborative efforts, as well as the presentation of a case study on refining inhalation risk assessment for point of contact toxicity that uses a source-to-outcome approach with both in vitro and in silico methods. The preliminary agenda and additional information about presentations will be posted when available....

Human In Vitro Models for Respiratory Toxicology: Evaluation of Goblet Cell Hyperplasia, Mucus Production, and Ciliary Beating Assays

March 28, 2018
Robust non-animal models and assays for pulmonary toxicology are required to make competent product development and risk assessments for new materials requiring toxicity testing. Three in vitro assays (goblet cell hyperplasia [GCH], ciliary beat frequency [CBF], and MUC5AC quantitation) were evaluated for performance and reproducibility. To assess these assays, 6 laboratories contributed data using a common protocol utilizing IL-13 as an inducer of adverse mucociliary-relevant tissue changes. MatTek EpiAirway™ and Epithelix MucilAir™ 3D tissue models were used to evaluate endpoints...